Storia in 4 fonti

In Depth: U.S.’ Biotech Scrutiny Tests China’s Drugmakers Abroad

Chinese pharma companies are still striking global deals, but rising regulatory pressure is forcing buyers and sellers to rethink price, structure and risk

Raccontata da

Confronto fonti

4 prospettive sulla stessa storia

AI · summaries

caixinglobal.comStai leggendo1 mese fa

In Depth: U.S.’ Biotech Scrutiny Tests China’s Drugmakers Abroad

Chinese pharma companies are still striking global deals, but rising regulatory pressure is forcing buyers and sellers to rethink price, structure and risk

originale

Timeline cronologica

martedì 23 giugno 2026·endpoints.news
BIO board spoke with national security, health officials on China, CEO says
BIO makes China political strategy a top priority as US weighs outbound investment limits; CEO Crowley says biotech may fall under COINS Act.
giovedì 25 giugno 2026·statnews.com
Biosecure didn’t stop China’s rise in biotech. Some lawmakers want to do more
They're laying the groundwork for legislation and regulation to counter Chinese biopharma companies.

In Depth: U.S.’ Biotech Scrutiny Tests China’s Drugmakers Abroad

Confronto fonti

In Depth: U.S.’ Biotech Scrutiny Tests China’s Drugmakers Abroad

Timeline cronologica

BIO board spoke with national security, health officials on China, CEO says

Biosecure didn’t stop China’s rise in biotech. Some lawmakers want to do more

At BIO, tension over China biotech deal regulation looms

Biosecure didn’t stop China’s rise in biotech. Some lawmakers want to do more

BIO board spoke with national security, health officials on China, CEO says

In Depth: U.S.’ Biotech Scrutiny Tests China’s Drugmakers Abroad

At BIO, tension over China biotech deal regulation looms